Proprotein convertase subtilisin/kexin type 9: from the discovery to the development of new therapies for cardiovascular diseases
about
PCSK9 inhibitors - from discovery of a single mutation to a groundbreaking therapy of lipid disorders in one decade.Lipoprotein receptors and lipid enzymes in hepatitis C virus entry and early steps of infection.Short- and long-term effects of xuezhikang, an extract of cholestin, on serum proprotein convertase subtilisin/kexin type 9 levels.
P2860
Proprotein convertase subtilisin/kexin type 9: from the discovery to the development of new therapies for cardiovascular diseases
description
2012 nî lūn-bûn
@nan
2012 թուականին հրատարակուած գիտական յօդուած
@hyw
2012 թվականին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Proprotein convertase subtilis ...... es for cardiovascular diseases
@ast
Proprotein convertase subtilis ...... es for cardiovascular diseases
@en
Proprotein convertase subtilis ...... es for cardiovascular diseases
@nl
type
label
Proprotein convertase subtilis ...... es for cardiovascular diseases
@ast
Proprotein convertase subtilis ...... es for cardiovascular diseases
@en
Proprotein convertase subtilis ...... es for cardiovascular diseases
@nl
prefLabel
Proprotein convertase subtilis ...... es for cardiovascular diseases
@ast
Proprotein convertase subtilis ...... es for cardiovascular diseases
@en
Proprotein convertase subtilis ...... es for cardiovascular diseases
@nl
P2860
P356
P1433
P1476
Proprotein convertase subtilis ...... es for cardiovascular diseases
@en
P2093
Nicola Ferri
P2860
P304
P356
10.6064/2012/927352
P407
P50
P577
2012-09-11T00:00:00Z